Skip to main content

Advertisement

Table 1 Demographics and disease characteristics of the subject who received at least one dose of obinutuzumab

From: Safety and efficacy of obinutuzumab in Chinese patients with B-cell lymphomas: a secondary analysis of the GERSHWIN trial

Variable CLL (n = 12) DLBCL (n = 23) FL (n = 13) Overall (n = 48)
Age at baseline (years)
 Mean (sd) 60.7 (12.0) 53.3 (15.8) 55.1 (8.8) 55.6 (13.4)
Gender [n (%)]
 Male 7 (58.3) 11 (47.8) 8 (61.5) 26 (54.2)
 Female 5 (41.7) 12 (52.2) 5 (38.5) 22 (45.8)
Weight (kg)
 Mean (sd) 60.83 (11.44) 62.33 (9.86) 64.27 (12.49) 62.48 (10.85)
Height (cm)
 Mean (sd) 161.0 (5.0) 164.1 (7.1) 166.3 (10.7) 163.9 (7.9)
ECOG at baseline [n (%)]
 0 2 (16.7) 8 (34.8) 8 (61.5) 18 (37.5)
 1 10 (83.3) 15 (65.2) 5 (38.5) 30 (62.5)
Ann Arbor stage at diagnosisa [n (%)]
 I N/A 0 2 (15.4) 2 (5.6)
 II N/A 4 (17.4) 0 4 (11.1)
 III N/A 8 (34.8) 5 (38.5) 13 (36.1)
 IV N/A 7 (30.4) 3 (23.1) 10 (27.8)
 Missing N/A 4 (17.4) 3 (23.1) 7 (19.4)
Binet stagea [n (%)]
 Stage A 1 (8.3) N/A N/A 1 (8.3)
 Stage B 6 (50.0) N/A N/A 6 (50.0)
 Stage C 2 (16.7) N/A N/A 2 (16.7)
 Unknown 3 (25.0) N/A N/A 3 (25.0)
Number of previous lines of treatment
 Median 2.0 2.0 3.0 2.0
 Minimum–maximum 1–7 1–11 1–6 1–11
Best response of prior treatment [n (%)]
 CR 1 (8.3) 9 (39.1) 2 (15.4) 12 (25.0)
 PR 8 (66.7) 9 (39.1) 7 (53.8) 24 (50.0)
 SD 1 (8.3) 2 (8.7) 0 3 (6.3)
 PD 0 2 (8.7) 0 2 (4.2)
 Missing 2 (16.7) 1 (4.3) 4 (30.8) 7 (14.6)
Duration of best response
 n 6 18 7 31
 Mean (sd) (days) 355.2 (604.2) 152.5 (119.2) 159.4 (136.4) 193.3 (281.3)
  1. CLL chronic lymphocytic leukemia, CR complete response, DLBCL diffuse large B-cell lymphoma, ECOG Eastern Cooperative Oncology Group, FL follicular lymphoma, N/A not applicable, PR partial response, SD stable disease, sd standard deviation
  2. a Patients were assessed according to Ann Arbor staging criteria for non-Hodgkin lymphoma and Binet staging criteria for CLL